Cullinan Therapeutics will present updated Phase 1 data for CLN-049 and velinotamig (CLN-803) across four posters at the 68th ASH Annual Meeting in December, highlighting potential safety and therapeutic efficacy.
Cullinan Therapeutics will present updated Phase 1 data for CLN-049 and velinotamig (CLN-803) across four posters at the 68th ASH Annual Meeting in December, highlighting potential safety and therapeutic efficacy.